Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial
This study did not demonstrate statistical non-inferiority of 1-mg/day DNG treatment over 2-mg/day DNG treatment for pain relief. These results suggest that the 2-mg/day dose may offer more robust analgesic effects, particularly during the early treatment phase. However, 1-mg/day DNG still showed meaningful symptom improvement with fewer adverse events than 2-mg/day DNG, supporting its potential use in selected patients requiring long-term therapy. Trial Registration Japan Registry of Clinical Trials, trial registration number: jRCTs041210016.
Authors
- Takuma Ishihara (ORCID: https://orcid.org/0000-0002-1979-8310)
- Kyoko Kikuno (ORCID: https://orcid.org/0009-0005-8903-3574)
- Kenro Chikazawa (ORCID: https://orcid.org/0000-0002-8839-4483)
- Masanori Isobe (ORCID: https://orcid.org/0000-0002-5899-9932)
- Ken-ichirou Morishige (ORCID: https://orcid.org/0000-0001-7869-1428)
- Tatsuro Furui (ORCID: https://orcid.org/0000-0003-4855-219X)
- Ryuta Asada (ORCID: https://orcid.org/0000-0003-2228-1272)
Institutions
- Jichi Medical University (JP)
- Osaka Prefectural Medical Center (JP)
- Nagoya City University (JP)
- Osaka City General Hospital (JP)
- Gifu University Hospital (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s12325-025-03397-z
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00